Previous 10 | Next 10 |
Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...
Incomplete biomarker testing fails to meet current medical guideline standards, placing more than 60 percent 1 of advanced colorectal cancer patients at risk of receiving a less effective treatment Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company,...
Growth at diagnostic testing expert Guardant Health (NASDAQ: GH) appears to be slowing down. But the company still expects to put up revenue growth of at least 26% this year, which isn't too shabby. And as Fool.com contributors Brian Orelli and Keith Speights discuss in this video f...
Shares of Guardant Health (NASDAQ: GH) were sinking 7.9% as of 3:05 p.m. EST on Thursday. The genomics company didn't report any news that would cause its stock to slide. Instead, Guardant Health's shares were pulled down by the broader market sell-off. Growth stocks are usu...
A picks-and-shovels precision medicine play that doesn't tend to grab headlines, CareDx (NASDAQ: CDNA) describes itself as "focused on better outcomes through personalized transplant surveillance." Its suite of offerings encompasses the spectrum of transplant medicine: waitlist mana...
Guardant Health, Inc. (Nasdaq: GH) has CE-marked Guardant360 ® CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). The test is also approved as a companion diagnostic to identify...
Shares of Guardant Health (NASDAQ: GH) were sinking 7.2% as of 11:08 a.m. EST on Thursday. The decline came after the company reported its fourth-quarter results following the market close on Wednesday. Guardant Health announced Q4 revenue of $78.3 million, up 25% year over ...
Guardant Health (NASDAQ: GH) started 2021 with a bang. The stock soared 39% year to date at one point earlier this month. It has since given up more than half of that gain, though, and its shares are likely to fall even more. The liquid biopsy pioneer announced its fourth-quarte...
Guardant Health, Inc. (GH) Q4 2020 Earnings Conference Call February 24, 2021 17:00 ET Company Participants Carrie Mendivil - Investor Relations Helmy Eltoukhy - Co-Founder & Chief Executive Officer AmirAli Talasaz - Co-Founder & President Mike Bell - Chief Financial Officer Conferenc...
Image source: The Motley Fool. Guardant Health Inc (NASDAQ: GH) Q4 2020 Earnings Call Feb 24, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Guardant Health Inc (GH) Q4 2020 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...